<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603795</url>
  </required_header>
  <id_info>
    <org_study_id>EPAG 2015</org_study_id>
    <nct_id>NCT03603795</nct_id>
  </id_info>
  <brief_title>Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy</brief_title>
  <acronym>EPAG2015</acronym>
  <official_title>A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag
      administered to elderly patients with Acute Myeloid Leukemia (AML) receiving induction
      chemotherapy. A phase II multicenter and randomized placebo-controlled study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized 1:1 to receive Eltrombopag or matching placebo, in double
      blinded.

      To compare overall survival rate at 12 months between the two arms, with or without 200 mg of
      Eltrombopag daily after induction chemotherapy

      Arm A : Eltrombopag 200 mg (100 mg/day for east Asian heritage) once daily from day 11 of
      induction chemotherapy to AML response evaluation or platelets count &gt; 100 x 10 Giga/L
      (maximum day 45)

      Arm B : Placebo once daily from day 11 of induction chemotherapy to AML response evaluation
      or platelets count &gt; 100 x 10 Giga/L. (maximum day 45)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization between 2 arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overal survival rate</measure>
    <time_frame>12 months after beginning treatment</time_frame>
    <description>overall survival rate at month 12 (year 1) between the two arms, with or without 200 mg of Eltrombopag daily after induction chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR and CRi) at day 45</measure>
    <time_frame>At day 45</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia Free Survival at month 12 (one year)</measure>
    <time_frame>12 months after beginning treatment</time_frame>
    <description>relapse measurement before month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term survival</measure>
    <time_frame>2, 3 and 5 years after first treatment administration</time_frame>
    <description>Overall survival at 2, 3 and 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with platelets count &gt; 100 Giga/L at day 45</measure>
    <time_frame>At day 45</time_frame>
    <description>platelets count &gt;100 Giga/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet transfusion independence</measure>
    <time_frame>platelets count daily from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>More than 3 days with platelets count ≥ 10 Giga/L</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of accident haemorrhage events ≥ grade 3</measure>
    <time_frame>Until day 45</time_frame>
    <description>All accident haemorrhage event ≥ grade 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days with platelets count &lt;10 Giga/L</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of platelets count</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of platelets transfusion</measure>
    <time_frame>from baseline to the end of induction (day 45)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to platelets count &gt; 100 Giga/L</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of platelets count</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to peripheral blood polymorphonuclear neutrophils (PMN) counts &gt; 0.5 G/L</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of peripheral blood PMN count</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to haemoglobin counts &gt; 8 g/dl</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of haemoglobin count</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to red blood cells transfusion independence</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of Red blood cells count and transfusion monitoring</description>
  </other_outcome>
  <other_outcome>
    <measure>Eltrombopag-Emergent Adverse Events</measure>
    <time_frame>Until day 90</time_frame>
    <description>Incidence and severity of Eltrombopag-Emergent Adverse Events utilizing National Cancer Institute - Common Terminology Criteria (NCI-CTC) criteria v4.03</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>At baseline and at the end of induction (maximum up to day 45)</time_frame>
    <description>EORTC Quality of Life Questionnaire - Core Questionnaire (QLQ-C30). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.
Each of the multi-item scales includes a different set of items - no item occurs in more than one scale.
All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>55 patients will be randomized in the experimental arm A. If platelets counts &lt; 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts &gt; 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets &lt; 100 x 10 Giga/L.
Chemotherapy administration would be performed among standard practice:
Daunorubicin: 60 mg/m² D1 to D3
Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7
Lomustine (CCNU): 200 mg/m² per os, at D1.
200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.
Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count &gt; 100 x 10 Giga/L (maximum day 45)
Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.
Chemotherapy administration would be performed among standard practice:
Daunorubicin: 60 mg/m² D1 to D3
Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7
Lomustine (CCNU): 200 mg/m² per os, at D1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Eltrombopag concomitant with induction chemotherapy in patient with AML</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Arm Eltrombopag</other_name>
    <other_name>Arm experimental A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo concomitant with induction chemotherapy patients with AML</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Arm placebo</other_name>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  60 years of age.

          -  AML de novo, except AML 3 and AML 7.

          -  AML with no adverse cytogenetic according to Medical Research Council (MRC) 2010
             classification.

          -  Subjects should be eligible for intensive chemotherapy by Daunorubicine, cytarabine,
             Lomustine.

          -  Eastern Cooperative Oncology Group (ECOG) &lt; 3 (appendix 1).

          -  SORROR ≤ 3 (appendix 2).

          -  Adequate baseline organ function defined by the criteria below:

               -  Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN) range except cases clearly
                  not indicative of inadequate liver function

               -  Alanine Aminotransferase (ALAT) and Aspartate Aminotransferase (ASAT) ≤ 3 x ULN

               -  Creatinin ≤ 1.5 x ULN

          -  Adequate cardiac function with Left Ventricular Ejection fraction (LVEF) ≥50%

          -  Absence of any psychological, familial, sociological or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule.

          -  Women will be menopausal to be enrolled

          -  The patient must give written (personally signed and dated) informed consent before
             completing any study-related procedure which means assessment or evaluation that would
             not form part of the normal medical care of the patient and before the start of
             induction chemotherapy.

          -  Affiliated to the French Social Security (Health Insurance).

        Exclusion criteria

          -  Subjects with a diagnosis of acute promyelocytic (M3) or megakaryocytic leukemia (M7).

          -  AML with adverse cytogenetic according to the MRC 2010 classification.

          -  AML secondary to Myelodysplastic syndrome (MDS), Myeloproliferative neoplasm (MPN)

          -  Clinical symptoms suggesting active central nervous system leukemia, or presence of
             extramedullary AML.

          -  Previous exposure to anthracycline.

          -  Previous AML treatment other than hydroxyurea.

          -  Treatment with an investigational drug within 30 days or 5 half-life whichever is
             longer, preceding the first dose of study medication.

          -  History of thromboembolic event or other condition requiring ongoing use of
             anticoagulation either with warfarin or low molecular-weight heparin.

          -  History of another malignancy within the past three years except basal cell carcinoma
             of the skin or carcinoma in situ of the cervix.

          -  Pre-existing cardiovascular disease (including congestive heart failure, New York
             Heart Association (NYHA) Grade III/IV), or arrhythmia known to increase the risk of
             thromboembolic events (e.g. atrial fibrillation), or subjects with a QTc &gt;450 msec
             (QTc &gt;480 msec for subjects with Bundle Branch Block).

          -  Patient requiring platelets transfusion with platelets &gt; 10 x 10 Giga/L, for whatever
             reason.

          -  History of treatment with romiplostim or other Thrombopoietin receptor (TPO-R)
             agonists.

          -  Uncontrolled active infection.

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would place the participant at an unacceptable risk or prevent them from giving
             informed consent.

          -  Known active HIV, Hepatitis B or C infection.

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud PIGNEUX, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organization (FILO)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arnaud PIGNEUX, MD PD</last_name>
    <phone>+335 57 65 65 11</phone>
    <email>arnaud.pigneux@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ariane MINEUR, Mrs</last_name>
    <phone>+335 57 62 31 08</phone>
    <email>ariane.mineur@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU ANGERS - Maladies du sang</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathilde HUNAULT, Dr</last_name>
      <phone>02 41 35 45 82</phone>
      <email>mahunault@chu-angers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque - Hématologie</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne BANOS, Dr</last_name>
      <phone>+33 5 59 44 38 32</phone>
      <email>abanos@ch-cotebasque.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aurélie RAVINET, Dr</last_name>
      <phone>04 73 75 00 65</phone>
      <email>aravinet@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - Hématologie Clinique</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude-Eric BULABOIS, Dr</last_name>
      <phone>04 76 76 57 55</phone>
      <email>cebulabois@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes - Hématologie 2</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Norbert VEY, Pr</last_name>
      <phone>+33 4 91 22 36 95</phone>
      <email>veyn@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi - Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yosr HICHERI, Dr</last_name>
      <phone>+33 4 67 33 24 18</phone>
      <email>y-hicheri@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOPITAL E. MULLER - Hématologie</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario OJEDA-URIBE, Dr</last_name>
      <phone>+33(0)3 89 64 77 55</phone>
      <email>ojeda-uribem@ghrmsa.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU HOTEL DIEU - Hématologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre PETERLIN, Dr</last_name>
      <phone>+33(0)2 40 08 32 71</phone>
      <email>pierre.peterlin@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric JOURDAN, Dr</last_name>
      <phone>04 66 68 32 31</phone>
      <email>eric.jourdan@chu-nimes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU La Milétrie - Hématologie Clinique</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria-Pilar GALLEGO-HERNANZ, Dr</last_name>
      <phone>+33(0)5 49 44 44 44</phone>
      <email>maria-pilar.gallego-hernanz@chu-poitiers.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc BERNARD, Dr</last_name>
      <phone>02 40 08 32 71</phone>
      <email>marc.bernard@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre - Hématologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno LIOURE, Dr</last_name>
      <phone>+33(0)3 88 12 76 76</phone>
      <email>bruno.lioure@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian RECHER, Pr</last_name>
      <phone>+33 5 31 15 63 55</phone>
      <email>recher.christian@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sponsor FILO</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mélanie COTTOT, Mrs</last_name>
      <phone>+33247478899</phone>
      <email>m.dupin@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caroline BONMATI, Dr</last_name>
      <phone>03 83 15 52 49</phone>
      <email>c.bonmati@chu-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO internet site</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

